胸腺肽α_1对严重脓毒症患者的免疫调理作用

Immune regulation mechanism of thymosin - α1 on severe sepsis patients

目的 评价胸腺肽α1对严重脓毒症患者的免疫调理作用 方法 44例患者随机分成治疗组与对照组,对照组常规治疗加安慰剂,治疗组常规治疗加胸腺肽α1(迈普欣),疗程为10 d。结果 治疗组治疗后的CD14+单核细胞人类白细胞抗原-DR(HLA-DR)水平明显升高,而CRP、APACHEⅡ评分及器官功能障碍的数量显著下降,28 d死亡率亦显著下降。结论 胸腺肽α1可提高严重脓毒症患者免疫力,改善患者的预后。

Objective To study the immune regulation mechanism of thymosin - α1 on severe sepsis patients. Methods Total patients of 44 were divided into two groups randomly, therapy group and control group. The control group was given routine therapy and console drugs while the therapy group was given routine therapy and thymosin - α1 for ten days. Results Compared with the control group, the HLA - DR level in therapy group increased greatly while C response protein value, APACHE Ⅱ score and the number of organ dysfunction in therapy group decreased significantly. Moreover, the mortality in therapy group also decreased on the 28th day. Conclusions Thymosin - α1 may improve the immunological function of severe sepsis patients and ameliorate their prognosis